The OSUCCC Clinical Trials Office (CTO), rated """"""""Excellent to Outstanding"""""""" in the 1999 review, supports the centralized administration of protocol conduct, development, review, implementation, monitoring, regulatory compliance, and quality assurance. The CTO is a shared resource of the OSUCCC that provides centralized management of all clinical trials conducted within the OSUCCC. The mission of the CTO is to foster a supportive environment conducive to the conduct of clinical trials by OSUCCC members and to provide a centralized resource to OSUCCC investigators for protocol administration, tracking and monitoring, data management, regulatory guidance, and financial management necessary for the successful conduct of clinical trials in a methodologically-sound, expedient, and cost-effective manner. The CTO came under the medical leadership o! John Byrd, M.D., and administrative leadership of Susan Ebert, R.D., M.S., in 2001. Since that time, the clinical research staff of Radiation Oncology, Stem Cell Transplant Program, Head & Neck Oncology, The Cancer and Leukemia Group B (CALGB), The AIDS-Related Malignancy Consortium (AMC), The CLL Research Consortium, and The NCI/CTEP Phase I Program have been consolidated within the CTO. This effort of consolidation as well as new clinical research faculty recruits and a consequent 232% increase in accrual to investigator-initiated studies (580 in 1999 and 1,926 in 2003) has resulted in the current CTO staffing of 38.5 FTE for its 224 open protocols, including 12 funded through NCI R21 QuickTrial grants. With recent acquisition of 7,000 nsf of space for the CTO, plans are to consolidate 20 remaining research staff conducting select cooperative group trials (ACOSOG, NSABP, and GOG) over the next two years in order to finalize centralization of all cancer clinical research activities. The CTO has reinforced infrastructure in the past several years with the creation of two new position titles, Regulatory Coordinator and Financial Manager. In addition, management infrastructure was improved with the creation of two new supervisory roles, the Clinical Research Manager (who manages all research nurses) and Data Management Supervisor (who manages research associates). A new web-based Cancer Research Information System (CRIS) has been developed for use by the CTO staff that vastly improves tracking of all research activities and provides the OSUCCC leadership and membership with the tools to monitor progress; 2627 patients were entered on trials and registered into the CTO CRIS database during the most recent 12-month period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-33
Application #
7630226
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$334,851
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Kim, Yangjin; Yoo, Ji Young; Lee, Tae Jin et al. (2018) Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci U S A 115:4927-4932
Wang, Xinmei; Kwak, Kwang Joo; Yang, Zhaogang et al. (2018) Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. PLoS One 13:e0198552
Callahan, Catherine L; Bonner, Matthew R; Nie, Jing et al. (2018) Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors. Environ Res 161:418-424
Gopalakrishnan, Bhavani; Cheney, Carolyn; Mani, Rajeswaran et al. (2018) Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget 9:9706-9713
Hankey, William; Frankel, Wendy L; Groden, Joanna (2018) Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev 37:159-172
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Stover, Daniel G; Parsons, Heather A; Ha, Gavin et al. (2018) Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol 36:543-553
Kelly, Rachel S; Lasky-Su, Jessica; Yeung, Sai-Ching J et al. (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One 13:e0197049
ElNaggar, Adam C; Hade, Erinn M; O'Malley, David M et al. (2018) Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. Gynecol Oncol 151:501-505

Showing the most recent 10 out of 2602 publications